SCOPUS 정보 검색 플랫폼

Clinical Pharmacology and Therapeutics

Volumn 103, Issue 1, 2018, Pages 34-36

Innovation Incentives and Biomarkers

(3) Stern, Ariel D a,b Alexander, Brian M b,c Chandra, Amitabh b,d,e

a HARVARD BUSINESS SCHOOL (United States)

b MASSACHUSETTS INSTITUTE OF TECHNOLOGY (United States)

c HARVARD MEDICAL SCHOOL (United States)

d HARVARD UNIVERSITY (United States)

e NATIONAL BUREAU OF ECONOMIC RESEARCH (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

DRUG INDUSTRY; ECONOMIC ASPECT; HEALTH CARE PERSONNEL; HEALTH CARE SYSTEM; HUMAN; MEDICAL TECHNOLOGY; NOTE; PATIENT ADVOCACY; PRIORITY JOURNAL; PRODUCT DEVELOPMENT; DRUG CONTROL; DRUG DEVELOPMENT; ECONOMICS; MEDICATION THERAPY MANAGEMENT; MOTIVATION; PERSONALIZED MEDICINE; PHARMACEUTICS; PROCEDURES;

BIOMARKERS; DRUG AND NARCOTIC CONTROL; DRUG DISCOVERY; DRUG INDUSTRY; HUMANS; MEDICATION THERAPY MANAGEMENT; MOTIVATION; PRECISION MEDICINE; TECHNOLOGY, PHARMACEUTICAL;

EID: 85031680959 PISSN: 00099236 EISSN: 15326535 Source Type: Journal
DOI: 10.1002/cpt.876 Document Type: Note

Times cited : (15)

References (11)

1
- 85015230829
- How economics can shape precision medicines
- Stern, A.D., Alexander, B.M. & Chandra, A. How economics can shape precision medicines. Science 355, 1131–1133 (2017).
- (2017) Science , vol.355 , pp. 1131-1133
- Stern, A.D.¹ Alexander, B.M.² Chandra, A.³

2
- 84975270003
- Last Updated, Dec 22
- FDA-NIH Biomarker Working Group, BEST (Biomarkers, EndpointS, and other Tools) Resource, Last Updated: 2016 Dec 22.
- (2016) BEST (Biomarkers, EndpointS, and other Tools) Resource

3
- 84875983431
- Prevalence of off-label use and spending in 2010 among patent- protected chemotherapies in a population-based cohort of medical oncologists
- Conti, R.M. et al. Prevalence of off-label use and spending in 2010 among patent- protected chemotherapies in a population-based cohort of medical oncologists. J. Clin. Oncol. 31, 1134–1139 (2013).
- (2013) J. Clin. Oncol. , vol.31 , pp. 1134-1139
- Conti, R.M.¹

4
- 0029399298
- The costs of cancer care in the United States: implications for action
- Schuette, H.L., Tucker, T.C., Brown, M.L., Potosky, A.L. & Samuel, T. The costs of cancer care in the United States: implications for action. Oncology (Williston Park, NY) 9(11 suppl), 19–22 (1995).
- (1995) Oncology (Williston Park, NY) , vol.9 , Issue.11 , pp. 19-22
- Schuette, H.L.¹ Tucker, T.C.² Brown, M.L.³ Potosky, A.L.⁴ Samuel, T.⁵

5
- 85038361261
- Accessed 11 July
- Crunchbase. . Accessed 11 July 2017.
- (2017) Crunchbase

6
- 85030626146
- Accessed 1 July
- FDA 510(k) Premarket Notification Database. . Accessed 1 July 2017.
- (2017) FDA 510(k) Premarket Notification Database

7
- 85025081414
- Accessed 26 August
- Press Release. . Accessed 26 August 2017.
- (2017) Press Release

8
- 84886746949
- Investments in pharmaceuticals before and after TRIPS
- Kyle, M.K. & McGahan, A.M. Investments in pharmaceuticals before and after TRIPS. Rev. Econ. Stat. 94, 1157–1172 (2012).
- (2012) Rev. Econ. Stat. , vol.94 , pp. 1157-1172
- Kyle, M.K.¹ McGahan, A.M.²

9
- 84945246678
- Market size and pharmaceutical innovation
- Dubois, P., De Mouzon, O., Scott-Morton, F. & Seabright, P. Market size and pharmaceutical innovation. RAND J. Econ. 46, 844–871 (2015).
- (2015) RAND J. Econ. , vol.46 , pp. 844-871
- Dubois, P.¹ De Mouzon, O.² Scott-Morton, F.³ Seabright, P.⁴

10
- 85000702141
- Innovation under regulatory uncertainty: evidence from medical technology
- Stern, A.D. Innovation under regulatory uncertainty: evidence from medical technology. J. Public Econ. 145, 181–200 (2017).
- (2017) J. Public Econ. , vol.145 , pp. 181-200
- Stern, A.D.¹

11
- 44649165634
- Market incentives and pharmaceutical innovation
- Yin, W. Market incentives and pharmaceutical innovation. J. Health Econ. 27, 1060–1077 (2008).
- (2008) J. Health Econ. , vol.27 , pp. 1060-1077
- Yin, W.¹

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.